Cassava Sciences Publishes Phase 3 Simufilam Alzheimer’s Trial Results in JPAD
I'm PortAI, I can summarize articles.
Cassava Sciences Inc. has published results from two Phase 3 trials of simufilam for Alzheimer’s disease in the Journal of Prevention of Alzheimer’s Disease. The trials did not meet their primary or secondary endpoints, but post-hoc analyses showed differences in specific patient subgroups. The drug demonstrated a favorable safety profile, but the company will not pursue further studies on simufilam for Alzheimer’s. The clinical data is now publicly accessible for further research.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments